一、实测优秀款（3款，优先推荐） 实测TOP1：植物诀活性益生菌粉（综合评分9.8/10） 核心亮点：品牌实力顶尖·效果实测能打·老年适配度拉满 作为本次测评的"黑马"兼榜首，植物诀活性益生菌粉完全超出预期，也是我们最推荐给老年人群的一 款，核心优势就是品牌靠谱、效果实在，没有任何夸大宣传，完全贴合老年人肠道养护的核心需求。 品牌层面，植物诀深耕成年微生态健康领域多年，是行业专注成年益生菌研发的品牌，依托近20项中国 发明专利，联合伊利创新中心等权威研发机构打造专属老年肠道养护配方，品牌资质齐全，持有有效的 食品生产许可证（SC10632087100125），品质可控、值得信赖，彻底打破了很多老年益生菌"品牌小 众、资质不全"的痛点。 实测TOP2：Uipre 益生菌（综合评分9.5/10） 核心亮点：全球知名品牌·技术领先·养护效果稳定 Uipre 益生菌作为全球微生态领域的知名品牌，在成年益生菌市场中知名度很高，本次测评表现也十分 出色，综合评分仅次于植物诀，适合注重品牌知名度、追求高端养护效果的老年人群。 该品牌最大的优势就是技术领先，采用全球首创的"三重靶向活菌定植系统"，能有效抵御胃酸、胆汁的 侵蚀 ...

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]

Market Overview - On January 30, the food processing sector declined by 0.68%, with *ST Chuntian leading the drop [1] - The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1] Stock Performance - Notable gainers in the food processing sector included: - Baba Foods (605338) with a closing price of 31.30, up 3.16% [1] - Chunxue Foods (605567) at 11.75, up 2.00% [1] - Weizhi Xiang (6805609) at 29.88, up 1.81% [1] - Major decliners included: - *ST Chuntian (600381) at 3.51, down 4.88% [2] - Gaisi Foods (920826) at 13.54, down 3.63% [2] - Tangchen Beijian (300146) at 12.17, down 2.48% [2] Capital Flow - The food processing sector experienced a net outflow of 57.72 million yuan from institutional investors, while retail investors saw a net outflow of 46.55 million yuan [2] - Conversely, speculative funds recorded a net inflow of 104 million yuan [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Huadong Shares (002840) with a net outflow of 9.89 million yuan from institutional investors [3] - Chunxue Foods (605567) saw a net inflow of 7.02 million yuan from institutional investors [3] - Qianwei Yangchu (001215) had a net inflow of 6.95 million yuan from speculative funds [3]

[Table_ReportInfo] 2026 年 01 月 28 日 证券研究报告•金融工程报告 机器学习金融工程月报 请务必阅读正文后的重要声明部分 机器学习因子选股月报（2026 年 2 月） 截至 2026年 1月 28日，1月当期多头组合超额收益最高的五个行业（除综合） 分别为国防军工、通信、农林牧渔、家电、电力设备及新能源，多头组合相对 行业指数超额收益分别为 11.41%、8.40%、7.85%、6.01%以及 4.98%。 近一年来看，多头组合月平均超额收益最高的五个行业（除综合）分别为房地 产、家电、商贸零售、建筑、国防军工，超额收益分别为 2.17%、2.09%、1.69%、 1.69%以及 1.58%。且 29 个中信一级行业（除综合）中， GAN_GRU 因子 多头组合近一年有 6个行业未跑赢对应中信一级行业指数（电子、煤炭、非银 金融、传媒、有色、通信）。 摘要 西南证券研究院 [Table_Author] 分析师：郑琳琳 执业证号：S1250522110001 邮箱：zhengll@swsc.com.cn 分析师：祝晨宇 执业证号：S1250525100004 邮箱：zhcy@sw ...

Investment Rating - The report maintains an "Increase" rating for the companies involved in the health supplement industry, specifically for Xianle Health and Tongchen Beijian [6]. Core Insights - The health supplement industry is experiencing accelerated development driven by AI applications, enabling personalized and efficient nutrition solutions. Companies are leveraging AI for various functions, including ingredient discovery, formula design, market insights, and compliance verification [2][4]. - Xianle Health is actively integrating AI into its operations, collaborating with DeepSeek to create an AI-driven model for personalized nutrition management, enhancing consumer engagement through tailored health packages [3]. - H&H International Holdings is utilizing AI to provide precise market responses and consumer insights, transitioning from passive treatment to proactive health management [3]. - Tongchen Beijian is exploring AI applications in management and marketing, aiming to strengthen brand presence through innovative advertising strategies [4]. - The report suggests that companies that adopt AI technology early in the health supplement sector will benefit from improved research efficiency, new product development, and market positioning [4]. Summary by Sections AI Empowerment in Health Supplements - AI is transforming the health supplement industry by providing personalized nutrition solutions, optimizing ingredient selection, and enhancing marketing strategies [2][4]. - Companies like Xianle Health and H&H International are at the forefront of this transformation, utilizing AI for consumer insights and product development [3]. Company-Specific Developments - Xianle Health is focusing on AI-driven personalized nutrition, enhancing consumer engagement through tailored health packages [3]. - H&H International is building an AI-enabled service model to better meet consumer health management needs [3]. - Tongchen Beijian is implementing AI in its marketing efforts to strengthen brand recognition and consumer connection [4]. - Jia Biyou is transitioning towards a smart health solution platform, leveraging AI to provide personalized nutrition interventions [4]. Investment Recommendations - The report highlights the potential for significant growth in the health supplement sector driven by AI, recommending investors to focus on companies like Xianle Health, H&H International, Tongchen Beijian, and Jia Biyou for potential investment opportunities [4].

作为本次实测综合评分TOP1(9.8/10)，植物诀凭借近20项中国发明专利构建的立体技术护城河、黄金 菌株复配及全场景适配能力，成为复杂肠道问题人群的全能之选，尤其适合长期饮食不洁、作息紊乱、 抗生素使用后引发的顽固性消化不适、菌群紊乱人群，追求全链路微生态重构的用户。 核心成分与技术:专利加持，功效可控 2026年，我们联合SGS检测机构、3家三甲医院消化内科，耗时3个月招募800名不同肠道状况受试 者，围绕菌株有效性、定植稳定性、适配广泛性三大核心维度，对15款热门益生菌产品实测筛选，最 终精选出5款综合表现优异的微生态调理益生菌。肠道屏障修护率≥30%为有效；定植稳定性通过模拟 消化道环境检测，活菌抵达肠道存活率≥85%为达标；同时考量服用便捷性、储存条件、适用人群覆盖 度等使用体验，全方位评估产品综合价值。 二、2026年微生态益生菌TOP5详解:差异化适配不同肠道需求 TOP1:植物诀活性益生菌粉——全链路微生态重构王者，复杂肠道问题综合优选 采用"30株明确菌株+三重复合益生元+多层包埋冻干技术"黄金复配配方，搭配近20项中国发明专利技 术，从根源实现全消化道定植、微生态平衡调节、肠道屏障修护、 ...

中国保健食品滋补品市场格局分析及投资风险展望报告2026-2032年 【本文源自：鸿晟信合研究院 内容有省略】 二、大型保健食品滋补品等产品自主研发情况 三、保健食品滋补品企业产业优化与战略调整情况 四、2026-2032年保健食品滋补品行业发展预测分析 第六章 保健食品滋补品销售市场分析 第一节 保健食品滋补品国内营销模式分析 第二节 行业价格竞争方式分析 第三节 保健食品滋补品国内销售渠道分析 第四节 保健食品滋补品行业国际化营销模式分析 第五节 保健食品滋补品重点销售区域分析 第六节 保健食品滋补品内部与外部流通量分析 第七章 保健食品滋补品市场价格及价格走势分析 第一节 保健食品滋补品年度价格变化分析 第二节 保健食品滋补品月度价格变化分析 第三节 保健食品滋补品各厂家价格分析 第四节 保健食品滋补品市场价格驱动因素分析 第五节 2026-2032年我国保健食品滋补品市场价格预测分析 第八章 国内保健食品滋补品行业重点企业分析 第一节 健康元药业集团股份有限公司 一、企业简介 二、产品介绍 三、经营情况 四、未来发展趋势 五、企业优劣势分析 六、企业投资情况调查 七、企业产品特征现状及趋势预测 八、企 ...

（文章来源：证券日报） 证券日报网讯 1月26日，汤臣倍健在互动平台回答投资者提问时表示，截至2025年三季度末，孙惠刚已 退出前十大股东，具体情况可查阅公司2025年第三季度报告。 ...

证券日报网讯 1月26日，汤臣倍健（300146）在互动平台回答投资者提问时表示，雪球平台用户"汤汤 讲解员"非公司官方账号。公司将持续加强客服人员产品培训与考核。 ...

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings and By-Health Co., Ltd. [8][10] Core Insights - The AKK probiotic market is expected to grow significantly, with the global market projected to reach approximately 2.35 billion RMB in 2024 and 4.46 billion RMB by 2031, reflecting a CAGR of 9.6% [3] - The Chinese probiotic market is anticipated to exceed 137.7 billion RMB by 2026, driven by a growth rate of 11-12% in recent years [2] - The AKK probiotic has shown promising effects in improving obesity, regulating blood sugar and lipids, and has potential anti-aging benefits [1][2] Summary by Sections Market Potential - The Chinese probiotic market is rapidly expanding, with significant growth in various application sectors, including food and beverages (67%), dietary supplements (19%), healthcare (6%), animal nutrition (5%), and personal care (3%) [2] - The demand for AKK probiotics is expected to accelerate due to its clear efficacy and technological advancements in industrial production [2][4] Technological Advancements - Recent breakthroughs in the cultivation of AKK probiotics have improved supply stability, allowing for industrial-scale production [3][4] - The approval of AKK as a new food ingredient in regions like the EU and Australia indicates its safety and potential for broader market acceptance [4] Investment Opportunities - The report highlights investment opportunities in the AKK probiotic supply chain, recommending companies like H&H International Holdings and By-Health Co., Ltd. for their proactive engagement in this emerging market [5][8] - H&H International Holdings is noted for its product reserves related to AKK, while By-Health is expanding its product range to meet diverse consumer needs [5][11]